Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2008)
36 slides from Nanosonics's shareholder meeting presentation, Nov 18, 2008
Slide 1: Nanosonics Limited (NAN) Annual General Meeting
For personal use only Nanosonics Limited (NAN) Annual General Meeting 18th November 2008
Slide 2: Proceedings
Proceedings For personal use only • Opening and Welcome • Quorum • Ordinary business • Resolution 1 - Election of a Director - Dr David Fisher • Resolution 2 - Election of a Director - Mr David Radford • Resolution 3 - Election of a Director - Dr Ron Weinberger • Resolution 4 - Adoption of Remunerat
Slide 3: Annual General Meeting - Chairman
For personal use only Annual General Meeting (NAN) Maurie Stang - Non-Executive Chairman 18th November 2008
Slide 4: Infections are a worldwide and widespread problem in healthcare
Infections are a worldwide and widespread For personal use only problem in today‘s healthcare environment • Australia: 150,000 healthcare associated infections and 7,000 deaths each year • United States: 2 million healthcare associated infections and 100,000 deaths each year • Europe, e.g. United Ki
Slide 5: Real World Problems
For personal use only Real World Problems
Slide 6: Expansion through partnerships
Expansion through partnerships For personal use only Nanosonics` OEMs / Global NanoNebulant™ Medical Co`s • Value added products Requirements • World-Class sterilisation+ tech • Instrument friendly process Offering • Rapid, instrument friendly process • Additional revenue opportunities • Standards c
Slide 7: Business Overview
For personal use only Business Overview David Radford - Director and CEO 18th November 2008
Slide 8: Highlights
Highlights For personal use only • EN ISO 13485:2003 quality approval • CE Mark obtained in May 08 • IP - Portfolio of 10 patents • CMDCAS approval in Sept 08 • Distributors appointed Scandinavia, Germany, France, Italy, Switzerland, New Zealand and Australia • NZ approval to market Nov 08 • Release
Slide 9: Business Metrics 2008
Business Metrics 2008 For personal use only Category Date Amount Quoted shares on issue @ 15 October 103 million Total shares on issue @ 15 October 195 million* Cash on hand @ 30 September A$ 22 million Cash burn @ 30 September A$ 0.7 million monthly Share price @ 14 November A$ 0.18 Market capitali
Slide 10: Our Shareholders
Our Shareholders For personal use only Institutions Private Investors Corporate Investors Custodians & Nominees Founders
Slide 11: Board and Senior Management
For personal use only Board David Radford (CEO) Senior Management Dr. Ron Weinberger, GM Rachael Moore, GM John Murtagh, GM Product Management & Regulatory Affairs Innovation & Technology Manufacturing Arjang Safa, GM David Radford, GM Manufacturing & Global Marketing & Chris Grundy, CFO Supply Chai
Slide 12: Competencies
Competencies For personal use only Role PhD Masters Bachelor Deg. Material Sciences 1 Chemical Sciences 7 3 5 Bacteriology/Virology 2 1 3 Physics 1 Industrial Design 4 Electrical Engineering 5 System Engineering 2 Business / Operational 4 9
Slide 13: Company Strategy
Company Strategy For personal use only • Develop and commercialise novel and innovative solutions for use in the prevention of microbial contamination • Trophon EPR demonstrates proof of concept and expandability of our technology into new product manifestations. • Targeted markets include healthcar
Slide 14: For personal use only
For personal use only
Slide 15: NanoNebulant: A Breakthrough Technology
NanoNebulant™: A Breakthrough Technology For personal use only Fa Op Ma Sc En st era co teria ala tor mp ls ble frie viron Po frie ati nd me int nd bil ly nta of ly ity lly ca re
Slide 16: Setting New Standards
Setting New Standards For personal use only Nanosonics` new standards
Slide 17: Nanosonics' Patent Families
Nanosonics’ Patent Families For personal use only Granted Patents • Improved Disinfection • Quaternary Ammonium Compound Liquid Disinfectant Membrane Sterilisation Space Disinfection (national phase) (national phase) Membrane Concentrator Improved Aerosol (national phase) (national phase) Membrane V
Slide 18: Trophon - A breakthrough in the world of medical disinfection
Trophon - A breakthrough in the world of For personal use only medical disinfection
Slide 19: Latest USA CDC guidelines
Latest USA CDC guidelines For personal use only • Supports the need for HLD for intracavity ultrasound probes between patients • Supports that aldehydes residues may be toxic for use in certain endo-vaginal procedures, particularly to embryos • States that aldehydes damage ultrasound probes even tho
Slide 20: Target Market Size
Target Market Size For personal use only Total Total Country/ Radiology O&G Other targeted available Region intracavity intracavity targeted market market ANZ 0.5M 1M 0.2M 1.7M 5.8M Europe 7M 16M 3M 26M 70M Canada 0.4M 0.9M 0.2M 1.5M 3.6M US 7M 11M 9M 27M 87M Asia 8.2M 17M 22M 47.2M 215M Japan 3.4M
Slide 21: Regulatory Requirements
Regulatory Requirements For personal use only 2009 Japan DEC 08 MOH Submission USA FDA Submission DEC 08 Australia Pending TGA approval NOV 08 New Zealand Product registration SEPT 08 Canada CMDCAS approval MAY 08 Europe CE Mark obtained
Slide 22: Launch Timeline
Launch Timeline For personal use only 2010 Japan DEC 09 USA Pending FDA approval JUN 09 Canada Canadian launch at CSDMS APR 09 Europe Staged launch Display at Medica with major OEM’s JAN 09 Mid-April delivery Australia / NZ NOV 08 Medica pre-launch SEP 08 ASUM Conference pre-launch
Slide 23: Mapping our future
Mapping our future For personal use only Established • Head office • In-house Manufacture • OEM and Dealer channel • Contracted Consumable Manufacture • Contracted Device Manufacture Headquarters Sydney (Australia)
Slide 24: Mapping our future
Mapping our future For personal use only Established • European Sales office • Business Development Manager • Statutory entity (legal protection) • Appointment of dealer network • Contracted Consumables Manufacture International Sales & Service Office Hamburg (Germany) Headquarters Sydney (Australia
Slide 25: Mapping our future
Mapping our future For personal use only Envisaged • Sales office • Appointment of dealer network • Contracted Consumables Manufacture International Sales & Service Office Hamburg (Germany) Regional Office USA Headquarters Sydney (Australia)
Slide 26: Mapping our future
Mapping our future For personal use only Envisaged • Joint Venture • Sales office • Contracted Consumables Manufacture International Sales & Service Office Hamburg (Germany) Regional Office USA Regional Office Asia/Pacific Headquarters Sydney (Australia)
Slide 27: Appointment of Distribution Channels
Appointment of Distribution Channels For personal use only Country / Region Dealer Status Australia ✔ New Zealand ✔ France ✔ Germany ✔ Italy ✔ Scandinavia ✔ Switzerland ✔
Slide 28: Future Distribution Channels FY09
Future Distribution Channels FY09 For personal use only Country / Region Dealer Status UK Final Negotiations Benelux Final Negotiations Canada Final Negotiations Spain Final Negotiations Poland Final Negotiations Russia Final Negotiations Portugal Final Negotiations
Slide 29: For personal use only
For personal use only
Slide 30: Production Capacity
Production Capacity For personal use only Manufacturing Roll-Out strategy is; • Flexible >> In-house or outsourced • Scalable >> Handle volume increases • Transferable >> Can be relocated • Responsive >> Rapid handling of demand fluctuations
Slide 31: Production Timeline
Production Timeline For personal use only • Extensive tooling program for custom designed parts Total value of A$850,000 • Procurement of electronic components completed • Additional parts on track for completion by December 2008 • Production of tooled parts on track for completion by December 2008
Slide 32: Expanding the product range
Expanding the product range For personal use only NanoNebulant technology is transferable and highly scalable to other applications Food applications Platform technology Scaleable Room / Industrial Cost effective Medical /Healthcare Environmentally friendly
Slide 33: Work in progress
Work in progress For personal use only Small endoscope Space disinfection Automated endoscope disinfector/steriliser washer and disinfector/steriliser Market potential: > $400M Market potential:> $1.9B Market potential: > $1B
Slide 34: Summary
Summary For personal use only • The Company is on track for commercialisation of the Trophon EPR in Q3-FY09 • Trophon EPR demonstrates proof of concept and allows for expansion into new products. Strong product pipeline developing - healthcare and non-healthcare sectors • The Company is developing i
Slide 35: For personal use only
For personal use only
Slide 36: For personal use only
i ex, AjUO OSN |CUOSIJOCd JOS